Show Chwan Health Care System has announced a partnership with Novotech, a clinical research organization (CRO) in the Asia-Pacific region, to enhance the quality and efficiency of international clinical trials for new drugs. The collaboration aims to leverage Novotech's expertise in clinical trial planning to expand clinical trial opportunities in Changhua and Tainan, ensuring that patients have access to the latest treatment technologies and accelerating the development of new drugs.
Chen Xiuzhu, Chief Operating Officer of Show Chwan Health Care System, emphasized the organization's commitment to improving clinical research capabilities and medical service quality. "Show Chwan Health Care System is dedicated to becoming a leading clinical trial research and execution center in China," Chen stated. The IRB Human Trial Committee and the HRPC Trial Research Subject Protection Center are in place to ensure the comprehensive protection of subjects participating in clinical trials.
Strategic Partnerships for Clinical Trial Advancement
Show Chwan Health Care System is actively forging partnerships with internationally recognized pharmaceutical companies, including AstraZeneca and BeiGene, to strengthen its clinical trial capabilities. The collaboration with Novotech will focus on the development of clinical trials and educational courses.
Novotech's Role and Expertise
Yooni Kim, Managing Director of Asia Pacific at Novotech, expressed enthusiasm for the partnership, highlighting Novotech's extensive experience with over 5,000 clinical trial projects, spanning Phase I to Phase IV trials and bioequivalence studies. Novotech has successfully conducted over 600 clinical trials in Taiwan, with a significant focus on Phase I and Phase II trials (approximately 34%).
"Our clients primarily include biotechnology and small to mid-size pharma companies conducting clinical trials in the Asia-Pacific region, the U.S., and Europe," Kim noted. Novotech employs over 3,000 individuals across 34 offices worldwide, providing comprehensive clinical development services across all trial phases. The organization adheres to the highest standards of ICH-GCP and global regulatory bodies, supported by an ISO9001-certified quality management system. Novotech's team possesses extensive therapeutic experience across various disease areas.
Impact on Drug Development and Patient Care
The collaboration between Show Chwan and Novotech is expected to drive the development and application of new drugs, accelerating their research and market entry. This will ultimately provide more treatment opportunities for patients, addressing unmet medical needs and improving patient outcomes.
